Mycophenolat Mofetil Sandoz (Mycophenolate Mofetil)

Mycophenolate Mofetil is used in the management of immune‑mediated processes that can lead to organ rejection.

• Kidney transplant rejection: helps maintain graft function by suppressing lymphocyte activity.
• Heart transplant rejection: reduces the risk of acute and chronic rejection episodes.
• Liver transplant rejection: supports long‑term graft survival by inhibiting immune proliferation.

• Mycophenolate Mofetil selectively inhibits inosine monophosphate dehydrogenase (IMPDH), a key enzyme in the de novo synthesis of guanosine nucleotides. By limiting guanosine availability, the drug impairs DNA synthesis in activated T and B lymphocytes, thereby reducing their proliferation and attenuating the immune response that drives transplant rejection.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: frequent loose stools, may lead to dehydration.
• Vomiting: occasional episodes, especially early in treatment.
• Abdominal pain: cramping or discomfort.
• Headache: transient, often resolves with continued use.
• Infections: increased susceptibility to bacterial, viral or fungal infections.

Serious or Rare Side Effects

• Bone marrow suppression: leukopenia, anemia, thrombocytopenia.
• Severe infections: opportunistic infections such as CMV or PCP.
• Malignancy: increased risk of lymphoproliferative disorders.
• Liver toxicity: elevated transaminases or hepatitis.
• Progressive multifocal leukoencephalopathy (PML): rare demyelinating disease.
• Reproductive toxicity: potential teratogenic effects.

Patients receiving Mycophenolate Mofetil should be monitored closely for safety concerns.

• Monitor blood counts: regular CBC to detect bone‑marrow suppression.
• Assess renal function: check serum creatinine and eGFR periodically.
• Evaluate liver enzymes: monitor ALT, AST for hepatic injury.
• Avoid live vaccines: increased risk of vaccine‑derived infection.
• Pregnancy risk: discuss contraception and potential fetal effects with a specialist.
• Store at room temperature: keep in the original container, protect from moisture and light.

Mycophenolate Mofetil may interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid)

• Azathioprine: additive bone‑marrow suppression.
• Live vaccines: heightened risk of infection.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): increase mycophenolate exposure.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: may worsen renal impairment.
• NSAIDs: combined use can affect kidney function.
• Antacids or cholestyramine: may reduce oral absorption of mycophenolate.